In November 2023, the FDA granted approval for tirzepatide under the brand name Zepbound for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity
The FDAs Center for Biologics Evaluation and Research (CBER) has not yet published guidance defining what highly similar means for a CAR-T product, creating a regulatory framework gap that functions as an additional de facto market protection
Network pharmacology was employed to investigate the molecular mechanism of SFN in treating psoriasis
Diabetes is a growing concern in the United States, with 35 million individuals impacted by type 2 diabetes mellitus (T2DM).[1] This chronic condition can lead to other health complications
At the Gulf Coast Institute of Rejuvenation , we believe that a well-balanced, high-protein, nutritionally dense diet can synergize with Semaglutide injections to help you achieve your weight loss goals